TransGenic Group

TransGenic Group ROCE

The Return on Capital Employed (ROCE) of TransGenic Group (2342.T) as of Nov 16, 2026 is 2.85 %. In the previous year, Return on Capital Employed (ROCE) was -13.19 % — a change of -121.61% (higher).

ROCE

2.85 %

YoY

-121.61%

Last updated:

In 2026, TransGenic Group's return on capital employed (ROCE) was 2.85 %, a -121.61% increase from the -13.19 % ROCE in the previous year.

The TransGenic Group ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
5.53 JPY
Jan 1, 2020
1.42 JPY
Jan 1, 2021
17.78 JPY
Jan 1, 2022
27.68 JPY
Jan 1, 2023
-4.96 JPY
Jan 1, 2024
1.72 JPY
Jan 1, 2025
-13.19 JPY
Jan 1, 2026
2.85 JPY
The TransGenic Group ROCE history
YEARROCEYoY
2.85 %-121.61%
-13.19 %-866.47%
1.72 %-134.69%
-4.96 %-117.92%
27.68 %+55.69%
17.78 %+1,152.57%
1.42 %-74.31%
5.53 %+296.26%
1.39 %-71.25%
4.85 %+195.40%
1.64 %+92.51%
0.85 %-128.47%
-3.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling TransGenic Group's Return on Capital Employed (ROCE)

TransGenic Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing TransGenic Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

TransGenic Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in TransGenic Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about TransGenic Group stock

Return on Capital Employed (ROCE) of TransGenic Group is 2.85 % in 2026.

Return on Capital Employed (ROCE) of TransGenic Group changed from -13.19 % to 2.85 %, representing a -121.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s TransGenic Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TransGenic Group

All Key Metrics — TransGenic Group